Geron (GERN) Stock Price, News & Analysis

Company Overview

Geron Corporation (NASDAQ:GERN) is a biopharmaceutical company focused on developing and commercializing treatments for blood cancers and other serious hematologic disorders. Its lead product is Rytelo (imetelstat), a telomerase inhibitor designed to target malignant cells by interfering with telomere maintenance.

In 2024, the U.S. Food and Drug Administration approved Rytelo for adults with lower-risk myelodysplastic syndromes who require regular red blood cell transfusions and have not responded adequately to, or have lost response to, or are ineligible for, erythropoiesis-stimulating agents. Geron markets Rytelo in the United States and continues to evaluate imetelstat in additional hematologic malignancies, including myelofibrosis.

Founded in 1990, Geron initially conducted research involving telomeres, telomerase and human embryonic stem cells before concentrating its business on oncology. The company is headquartered in Foster City, California, and is led by John A. Scarlett, who serves as chairman and chief executive officer.

Key Stats

• Today's Range: $1.20 to $1.24
• 50-Day Range: $1.19 to $1.63
• 52-Week Range: $1.04 to $2.01
• Volume: 2.16 million shs
• Average Volume: 13.71 million shs
• Market Capitalization: $787.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Hold

Geron Stock Analysis - MarketRank™

Geron scored higher than 41% of companies evaluated by MarketBeat, and ranked 563rd out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Hold

Consensus Rating

Geron has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Geron has a consensus price target of $4.00, representing about 223.9% upside from its current price of $1.24.

Amount of Analyst Coverage

Geron has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Geron are expected to grow in the coming year, from ($0.04) to $0.06 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Geron is -11.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Geron is -11.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Geron has a P/B Ratio of 3.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.70% of the float of Geron has been sold short.

Short Interest Ratio / Days to Cover

Geron has a short interest ratio ("days to cover") of 7.39.

Change versus previous month

Short interest in Geron has recently decreased by 10.57%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Geron does not currently pay a dividend.

Dividend Growth

Geron does not have a long track record of dividend growth.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.76

News Sentiment

Geron has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Geron this week, compared to 4 articles on an average week.

Search Interest

Only 6 people have searched for GERN on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Geron to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Geron insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.71% of the stock of Geron is held by insiders.

Percentage Held by Institutions

73.71% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GERN
• Previous Symbol: NASDAQ:GERN
• CIK: 886744
• Web: www.geron.com
• Phone: (650) 473-7700
• Fax: 650-473-7750
• Employees: 258
• Year Founded: 1990

Price Target and Rating

• Average Price Target for Geron: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: +226.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$83.50 million
• Net Margins: -34.17%
• Pretax Margin: -33.05%
• Return on Equity: -24.48%
• Return on Assets: -10.30%

Debt

• Debt-to-Equity Ratio: 0.55
• Current Ratio: 6.91
• Quick Ratio: 5.16

Sales & Book Value

• Annual Sales: $183.88 million
• Price / Sales: 4.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.35 per share
• Price / Book: 3.50

Miscellaneous

• Outstanding Shares: 642,470,000
• Free Float: 631,487,000
• Market Cap: $787.03 million
• Optionable: Optionable
• Beta: 0.61